# Juno Therapeutics, Inc., a Bristol-Myers Squibb Company: Phase 1 study in Clear Cell Renal Cell Carcinoma (ccRCC) (112 participants)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) |
| NCT ID | NCT07848295 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Clear Cell Renal Cell Carcinoma (ccRCC) |
| Intervention types | drug |
| Target enrollment | 112 |
| Site countries | United States, Belgium, France, Germany, Italy, Netherlands, Spain |
| Posted | 2026-09-30 |
| Planned start | 2026-12-31 |
| Event | Newly registered study |
| Event date | 2026-09-30 |

## Why this score
- Industry sponsor (buys outsourced services).
- 112 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07848295). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.